Kineta – Developing Novel Immunotherapies That Transform Patients’ Lives
Kineta, Inc. is a clinical stage biotechnology company committed to developing disruptive life science technologies that address unmet patient needs. The company’s management team leverages expertise in immunology, drug development and corporate finance to advance a focused pipeline of investigational drugs in oncology, neuroscience and virology.
A broad array of private, government and industry partners collaborate with Kineta to advance innovative research. Kineta has four novel immunotherapies in preclinical and clinical development with the opportunity for Fast Track Status and Priority Review Vouchers. Kineta has established “top tier” milestone driven strategic partnerships with Pfizer and Genentech that are accelerating the development of the RIG-I immuno-oncology and chronic pain programs.
“We are confident that Kineta is at the forefront of medical innovation that can transform the way we treat patients with a wide range of once-devastating diseases,” said Dr. Shawn Iadonato, Kineta CEO. “All across the country today, there is work being done in labs that may benefit patients and society for generations to come. The key is to ensure that these talented researchers have the tools, resources and the policy and regulatory environment to foster scientific innovation and novel therapies that patients are counting on.”
There is tremendous
market potential for Kineta’s immunotherapies, which address sizable and
growing markets. At present, the immuno-oncology
market represents a $37.5 billion opportunity that is projected to grow to
$124.9 billion in 2024.
Kineta represents the third biotechnology startup for the company’s founders. Overall, its model is designed to improve the chances of program advancement and the cost effectiveness of drug development.